PMID: 12377653Oct 16, 2002Paper

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease

Annals of Oncology : Official Journal of the European Society for Medical Oncology
Andreas JostingParticipating Centers

Abstract

An important variable affecting outcome in relapsed and refractory Hodgkin's disease (HD) is the potential of conventional salvage chemotherapy to reduce tumor volume before high-dose chemotherapy (HDCT) and autologous stem cell transplantation. Currently, the optimal salvage chemotherapy regimen for these patients is unclear. Since dexamethasone/cisplatin/cytarabine (DHAP) given at 3-4 week intervals has been shown to be very effective in patients with relapsed aggressive non-Hodgkin's lymphoma, we evaluated this regimen given at a median of 16-day intervals in patients with relapsed and refractory HD. Patients with relapsed or refractory HD were treated with two cycles of DHAP [dexamethasone 40 mg intravenously (i.v.) day 1-4, cisplatin 100 mg/m(2) i.v. as 24-h continuous infusion day 1, and cytarabine 2 g/m(2) i.v. 12q day 2]. Granulocyte colony-stimulating factor (G-CSF) was given at a dose of 5 micro g/kg from day 4 until day 13. Patients with partial remission (PR) or complete remission (CR) after two cycles of DHAP received sequential HDCT. The median age of the 102 patients included was 34 years (range 21-64 years). Forty-two percent of the patients had late relapse, 29% early relapse, 12% multiple relapse and 16% prima...Continue Reading

Citations

Jun 13, 2012·Nature Reviews. Clinical Oncology·Peter BorchmannAndreas Engert
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A EngertUNKNOWN ESMO Guidelines Working Group
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Dec 17, 2009·Hematology·John Kuruvilla
Mar 6, 2012·The Oncologist·Radhakrishnan Ramchandren
Aug 11, 2011·Haematologica·Stephanie HarelCatherine Poirot
Oct 26, 2013·Annals of Hematology·Eliza A HawkesIan Chau
May 14, 2011·Current Hematologic Malignancy Reports·Bastian von Tresckow, Andreas Engert
Jun 20, 2014·Current Hematologic Malignancy Reports·Francesca Montanari, Catherine Diefenbach
May 28, 2014·Annals of Hematology·Jorge LabradorRamón García-Sanz
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Jan 9, 2007·Journal of the American Animal Hospital Association·Chelsea B GreenbergMichael D Lucroy
Aug 26, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S GerrieJ M Connors
Jun 21, 2011·Advances in Hematology·S E Richardson, C McNamara
Nov 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Fernández de LarreaE Carreras
Jan 27, 2016·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·Ilhami BerberMustafa Ozgul
Jun 3, 2006·Current Problems in Cancer·Richard W TsangMichael Crump
May 30, 2015·Current Hematologic Malignancy Reports·Paul J Bröckelmann, Andreas Engert
Sep 17, 2004·Leukemia & Lymphoma·Dina IbrahimAyad Al-Katib
Aug 8, 2012·Critical Reviews in Oncology/hematology·Paolo G GobbiAlessandro Levis
Jan 26, 2011·Blood·John KuruvillaMichael Crump
May 18, 2016·British Journal of Haematology·Carmen MartínezUNKNOWN Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO)
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·YeeYie E LieskovskyRajni Agarwal
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas JostingAndreas Engert
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther SchellongUNKNOWN DAL/GPOH
Mar 10, 2016·Asia-Pacific Journal of Clinical Oncology·Jae-Cheol JoUNKNOWN CoOperative Study Group A for Hematology (COSAH)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.